SrasV1, Main, Curation, bibRecord, 004475

Antiviral drug discovery against SARS-CoV

Identifieur interne : 004475 ( Main/Curation ); précédent : 004474; suivant : 004476

Antiviral drug discovery against SARS-CoV

Auteurs : Yu-Shan Wu [Taïwan] ; Wen-Hsing Lin [Taïwan] ; John T.-A. Hsu [Taïwan] ; Hsing-Pang Flsieh [Taïwan]

Source :

Current medicinal chemistry [ 0929-8673 ] ; 2006.

RBID : Pascal:06-0496072

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Cysteine endopeptidases, Humains, Inhibiteurs de protéases (pharmacologie), Méthode des plages virales, Peptides (analyse), Protéines virales (antagonistes et inhibiteurs), RNA replicase (antagonistes et inhibiteurs), Tests de sensibilité microbienne (), Virus du SRAS ().
MESH :
- analyse : Peptides.
- antagonistes et inhibiteurs : Protéines virales, RNA replicase.
- pharmacologie : Antiviraux, Inhibiteurs de protéases.
Pascal (Inist)
- Animaux, Antiviral, Cysteine endopeptidases, Humains, Méthode des plages virales, Recherche développement, Médicament, Tests de sensibilité microbienne, Virus du SRAS, Virus syndrome respiratoire aigu sévère, Article synthèse, Criblage haut débit, Ciblage, Synthèse chimique, Peptide, Analogue, Composé non peptide, Inhibiteur protease, siRNA, Relation structure activité, Inhibiteur enzyme, Peptidases, RNA antisens, Criblage virtuel.
Wicri :
- topic : Médicament.

English descriptors

KwdEn :
- Analog, Animals, Antisense RNA, Antiviral, Antiviral Agents (pharmacology), Chemical synthesis, Cysteine Endopeptidases, Drug, Enzyme inhibitor, High throughput screening, Humans, Microbial Sensitivity Tests (methods), Non peptide compound, Peptidases, Peptides, Peptides (analysis), Protease Inhibitors (pharmacology), Protease inhibitor, RNA Replicase (antagonists & inhibitors), Research and development, Review, SARS Virus (drug effects), Severe acute respiratory syndrome virus, Small Interference RNA, Structure activity relation, Targeting, Viral Plaque Assay, Viral Proteins (antagonists & inhibitors), Virtual screening.
MESH :
- chemical , analysis : Peptides.
- chemical , antagonists & inhibitors : RNA Replicase, Viral Proteins.
- chemical , pharmacology : Antiviral Agents, Protease Inhibitors.
- drug effects : SARS Virus.
- methods : Microbial Sensitivity Tests.
- Animals, Cysteine Endopeptidases, Humans, Viral Plaque Assay.

Abstract

Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M^pro; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000448
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000542
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000504
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004705
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002167
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002167
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002287
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001575
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001575
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001575
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004187

Links to Exploration step

Pascal:06-0496072

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Hsinchu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0496072</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0496072 INIST</idno>
<idno type="RBID">Pascal:06-0496072</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000448</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000542</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000504</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000504</idno>
<idno type="wicri:doubleKey">0929-8673:2006:Wu Y:antiviral:drug:discovery</idno>
<idno type="wicri:Area/Main/Merge">004705</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16842194</idno>
<idno type="wicri:Area/PubMed/Corpus">002167</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002167</idno>
<idno type="wicri:Area/PubMed/Curation">002167</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002167</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002287</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002287</idno>
<idno type="wicri:Area/Ncbi/Merge">001575</idno>
<idno type="wicri:Area/Ncbi/Curation">001575</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001575</idno>
<idno type="wicri:doubleKey">0929-8673:2006:Wu Y:antiviral:drug:discovery</idno>
<idno type="wicri:Area/Main/Merge">004187</idno>
<idno type="wicri:Area/Main/Curation">004475</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Hsinchu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analog</term>
<term>Animals</term>
<term>Antisense RNA</term>
<term>Antiviral</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chemical synthesis</term>
<term>Cysteine Endopeptidases</term>
<term>Drug</term>
<term>Enzyme inhibitor</term>
<term>High throughput screening</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests (methods)</term>
<term>Non peptide compound</term>
<term>Peptidases</term>
<term>Peptides</term>
<term>Peptides (analysis)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protease inhibitor</term>
<term>RNA Replicase (antagonists & inhibitors)</term>
<term>Research and development</term>
<term>Review</term>
<term>SARS Virus (drug effects)</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Small Interference RNA</term>
<term>Structure activity relation</term>
<term>Targeting</term>
<term>Viral Plaque Assay</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Virtual screening</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cysteine endopeptidases</term>
<term>Humains</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Méthode des plages virales</term>
<term>Peptides (analyse)</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>RNA replicase (antagonistes et inhibiteurs)</term>
<term>Tests de sensibilité microbienne ()</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA Replicase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
<term>RNA replicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cysteine Endopeptidases</term>
<term>Humans</term>
<term>Viral Plaque Assay</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Antiviral</term>
<term>Cysteine endopeptidases</term>
<term>Humains</term>
<term>Méthode des plages virales</term>
<term>Recherche développement</term>
<term>Médicament</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
<term>Criblage haut débit</term>
<term>Ciblage</term>
<term>Synthèse chimique</term>
<term>Peptide</term>
<term>Analogue</term>
<term>Composé non peptide</term>
<term>Inhibiteur protease</term>
<term>siRNA</term>
<term>Relation structure activité</term>
<term>Inhibiteur enzyme</term>
<term>Peptidases</term>
<term>RNA antisens</term>
<term>Criblage virtuel</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M<sup>pro</sup>
; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</div>
</front>
</TEI>
<double idat="0929-8673:2006:Wu Y:antiviral:drug:discovery"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Hsinchu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0496072</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0496072 INIST</idno>
<idno type="RBID">Pascal:06-0496072</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000448</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000542</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000504</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000504</idno>
<idno type="wicri:doubleKey">0929-8673:2006:Wu Y:antiviral:drug:discovery</idno>
<idno type="wicri:Area/Main/Merge">004705</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Hsinchu</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>Miaoli County</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analog</term>
<term>Antisense RNA</term>
<term>Antiviral</term>
<term>Chemical synthesis</term>
<term>Drug</term>
<term>Enzyme inhibitor</term>
<term>High throughput screening</term>
<term>Non peptide compound</term>
<term>Peptidases</term>
<term>Peptides</term>
<term>Protease inhibitor</term>
<term>Research and development</term>
<term>Review</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Small Interference RNA</term>
<term>Structure activity relation</term>
<term>Targeting</term>
<term>Virtual screening</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiviral</term>
<term>Recherche développement</term>
<term>Médicament</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
<term>Criblage haut débit</term>
<term>Ciblage</term>
<term>Synthèse chimique</term>
<term>Peptide</term>
<term>Analogue</term>
<term>Composé non peptide</term>
<term>Inhibiteur protease</term>
<term>siRNA</term>
<term>Relation structure activité</term>
<term>Inhibiteur enzyme</term>
<term>Peptidases</term>
<term>RNA antisens</term>
<term>Criblage virtuel</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M<sup>pro</sup>
; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral drug discovery against SARS-CoV.</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350</wicri:regionArea>
<wicri:noRegion>Zhunan Town. Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16842194</idno>
<idno type="pmid">16842194</idno>
<idno type="doi">10.2174/092986706777584988</idno>
<idno type="wicri:Area/PubMed/Corpus">002167</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002167</idno>
<idno type="wicri:Area/PubMed/Curation">002167</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002167</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002287</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002287</idno>
<idno type="wicri:Area/Ncbi/Merge">001575</idno>
<idno type="wicri:Area/Ncbi/Curation">001575</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001575</idno>
<idno type="wicri:doubleKey">0929-8673:2006:Wu Y:antiviral:drug:discovery</idno>
<idno type="wicri:Area/Main/Merge">004187</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral drug discovery against SARS-CoV.</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35, Keyan Road, Zhunan Town. Miaoli County 350</wicri:regionArea>
<wicri:noRegion>Zhunan Town. Miaoli County 350</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T-A" last="Hsu">John T-A Hsu</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
</analytic>
<series><title level="j">Current medicinal chemistry</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cysteine Endopeptidases</term>
<term>Humans</term>
<term>Microbial Sensitivity Tests (methods)</term>
<term>Peptides (analysis)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>RNA Replicase (antagonists & inhibitors)</term>
<term>SARS Virus (drug effects)</term>
<term>Viral Plaque Assay</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cysteine endopeptidases</term>
<term>Humains</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Méthode des plages virales</term>
<term>Peptides (analyse)</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>RNA replicase (antagonistes et inhibiteurs)</term>
<term>Tests de sensibilité microbienne ()</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA Replicase</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
<term>RNA replicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cysteine Endopeptidases</term>
<term>Humans</term>
<term>Viral Plaque Assay</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cysteine endopeptidases</term>
<term>Humains</term>
<term>Méthode des plages virales</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M(pro); 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004475 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004475 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0496072
   |texte=   Antiviral drug discovery against SARS-CoV
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Antiviral drug discovery against SARS-CoV

Antiviral drug discovery against SARS-CoV

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri